Ignite Creation Date:
2024-07-17 @ 11:37 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06463665
Status:
RECRUITING
Last Update Posted:
2024-06-20
First Post:
2024-06-11
Brief Title:
Efficacy Safety of Olvimulogene Nanivacirepvec Platinum-doublet Physicians Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Sponsor:
Genelux Corporation
Organization:
Genelux Corporation
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Advanced Non-squamous Non-small-cell Lung Cancer |
| Advanced Squamous Non-Small Cell Lung Carcinoma |
| Metastatic Non-squamous Non Small Cell Lung Cancer |
| Metastatic Squamous Non-Small Cell Lung Carcinoma |
| Non-small Cell Lung Cancer |
| Non-small Cell Lung Cancer Stage III |
| Non-small Cell Lung Cancer Stage IV |
| Non-small Cell Lung Cancer Recurrent |
Keywords:
| Name | View |
|---|---|
| Olvi-Vec | View |
| virotherapy | View |
| viral therapy | View |
| immunotherapy | View |
| immunochemotherapy | View |
| combination therapy | View |
| vaccinia virus | View |
| platinum-doublet chemotherapy | View |
| pembrolizumab | View |
| nivolumab | View |
| cemiplimab | View |
| atezolizumab | View |
| durvalumab | View |
| anti-PD-1 | View |
| anti-PD-L1 | View |
| carboplatin | View |
| cisplatin | View |
| docetaxel | View |
| neoplasms by site | View |
| neoplasms | View |
| carcinoma | View |
| Neoplasms by Histologic type | View |
| Antineoplastic Agents Phytogenic | View |
| Antineoplastic Agents | View |
| Antimitotic Agents | View |
| Molecular Mechanisms of Pharmacological Action | View |
| Immune Checkpoint Inhibitors | View |
| NSCLC | View |
| NSCL cancer | View |
| chemoimmunotherapy | View |
| ICI | View |
| platinum resensitization | View |
| platinum resistant | View |
| chemoresistance | View |
| resensitize | View |
| olvimulogene nanivacirepvec | View |